Factors included were: age (≥60 vs. <60 years, gender (male vs. female), tumor type, RMH prognostic score, age, Eastern Cooperative Oncology Group (ECOG) performance status (0–1 vs. ≥2), treatment with RAF/MEK targeting agents vs. never treated with RAF/MEK targeting agent, any decrease in target lesion size vs. no decrease after referral to the phase 1 trial. Here, MAP2K7 is linked to neoplasm.